Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02558972 · ClinicalTrials.gov registry record · Phase 2
Northera Improves Postural Tachycardia Syndrome (POTS) and Postural Vasovagal Syncope (VVS)
A Phase 2 study, sponsored by New York Medical College.
- Terminated
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT02558972 is a Phase 2 study that was terminated before completion, run by New York Medical College. The registered enrollment target is 30 participants.
The verdict
NCT02558972, a Phase 2 study, was terminated before completion, sponsored by New York Medical College.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
Vasovagal syncope (VVS, simple faint) is the most common cause of transient loss of consciousness and represents the acute episodic form of orthostatic intolerance (OI). Postural tachycardia syndrome (POTS) is the common chronic form of OI. Both are defined by debilitating symptoms and signs while upright relieved by recumbency. Northera should therefore improve both sympathetic splanchnic arterial vasoconstriction and sympathetic splanchnic venoconstriction in POTS and VVS, and may represent an ideal drug to improve the orthostatic response in POTS and VVS.
Interventions
- DRUG Placebo
- DRUG Northera (Droxidopa)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2015-09 |
| Est. Completion | 2022-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02558972
The ClinicalTrials.gov registry entry for NCT02558972 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York Medical College, which has 47 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02558972 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02558972 about?
NCT02558972 is a clinical study titled "Northera Improves Postural Tachycardia Syndrome (POTS) and Postural Vasovagal Syncope (VVS)". Vasovagal syncope (VVS, simple faint) is the most common cause of transient loss of consciousness and represents the acute episodic form of orthostatic intolerance (OI). Postural tachycardia syndrome (POTS) is the common chronic form of OI. Both are defined by debilitating symptoms and signs while u...
What is the current status of trial NCT02558972?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2015-09. Estimated completion is 2022-12.
What interventions are being tested in trial NCT02558972?
The interventions under investigation include: Placebo (DRUG), Northera (Droxidopa) (DRUG).
Who is sponsoring clinical trial NCT02558972?
This trial is sponsored by New York Medical College, which has 47 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.